Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders,

Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report’s publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages. Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services. Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.

The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays. In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.

SCOPE OF THE REPORT
The “Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
A detailed assessment of the overall market landscape of the cell and gene therapy bioassay services market, providing information on their year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of offering (in vitro and in vivo), type of bioassay(s) offered (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).
A detailed competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, by taking into consideration their service strength (in terms of bioassay offering(s) and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).
Tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America, Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of offerings, type of bioassay(s) offered, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.
An insightful contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and types of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers.
A detailed analysis of the global events attended by the service providers, based on year of event, type of event, type of services involved and application area, and strategic initiatives taken by various cell and gene therapy bioassay service providers.
A case study of the overall landscape of cell and gene therapy therapeutics market, based on a number of parameters. The market landscape of cell therapies, features distribution of cell therapies across phase of development, therapeutic area and type of developer. Further, the market landscape of cell therapies, features distribution of gene therapies across phase of development of pipeline candidates and key therapeutic areas. The chapter also features information on the developers involved in the domain of cell and gene therapies.
An in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
An in-depth analysis of nearly 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of cell and gene therapy bioassay services market. We have provided an informed estimate of the evolution of the market for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED
Who are the leading services providers offering bioassay services related to cell and gene therapies?
What is the relative competitiveness of different cell and gene therapy bioassay service providers?
Which is the commonly offered bioanalytical service (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) related to cell and gene therapy?
What are the key trends within the cell and gene therapy bioassay service providers market?
What kind of initiatives are being taken by stakeholders engaged in this domain?
Which players are likely to partner with cell and gene therapy bioassay service providers?
How is the current and future opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to teleradiology services market?

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell and gene therapy bioassay services market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to bioassays and type of cell and gene therapy bioassays. It also highlights the importance of bioassay and challenges related to cell and gene therapy bioassays. Additionally, it provides a brief introduction to the concept of CROs, featuring a discussion on the role of contract service providers and prevalent outsourcing trends.

Chapter 4 provides a detailed assessment of the overall market landscape of cell and gene therapy bioassay service providers, including information on close to 50 stakeholders and a detailed analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of bioassay(s) offered (in vitro and in vivo), type of offerings (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).

Chapter 5 features an insightful competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, based on service strength (in terms of number of offering(s) of bioassays and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).

Chapter 6 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America. Each profile includes an overview of the company, financial (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, type of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.

Chapter 7 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.

Chapter 8 includes a contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and type of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers.

Chapter 9 includes a detailed analysis of the global events and strategic initiatives taken by the several cell and gene therapy bioassay service providers related to bioassays. The chapter features distribution of events on the basis of year of event, type of event, type of services involved and application area.

Chapter 10 is a case study of the overall landscape of cell and gene therapy therapeutics market, based on number of relevant parameters, such as phase of development, therapeutic area and type of developer, while highlighting key developers. The chapter also features information on the companies involved in the development of cell and gene therapies.

Chapter 11 features an in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.

Chapter 12 features an in-depth analysis of more than 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the cell and gene therapy services market for the time period 2021-2030. In order to provide details on the future outlook, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the cell and gene therapy bioassay services market.

Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES

1. 4D Molecular Therapeutics
2. AavantiBio
3. aaVective
4. AAVogen
5. AbbVie
6. AbClon
7. Abeona Therapeutics
8. Absorption Systems
9. Adaptimmune Therapeutics
10. Adelson Medical Research Foundation (AMRF)
11. Adicet Bio
12. Advanced Cell Diagnostics
13. Advantagene
14. Advaxis
15. Adverum Biotechnologies
16. Aeon Therapeutics
17. Affinia Therapeutics
18. AffyImmune Therapeutics
19. Agency for Science, Technology and Research (A*STAR)
20. AgenTus Therapeutics
21. AGTC
22. AIT Bioscience
23. Akouos
24. Allergan
25. Allogene Therapeutics
26. AlphaVax
27. Altasciences
28. Altheia Science
29. Altor Bioscience
30. Amarna Therapeutics
31. Ambulero
32. American Gene Technologies
33. Amgen
34. Amicus Therapeutics
35. AnaBioTec
36. Anaeropharma Science
37. AnGes
38. Angionetics
39. AnHui Medical University (AHMU)
40. ApolloBio
41. Applied StemCell
42. Arbele
43. Aruvant Sciences
44. ASC Therapeutics
45. Asklepios BioPharmaceutical (AskBio)
46. Atara Biotherapeutics
47. Atsena Therapeutics
48. Aurigon
49. Aurora Biopharma
50. Avance Biosciences
51. Avectas
52. Avomeen
53. AVROBIO
54. Axovant Gene Therapies
55. Baylor College of Medicine
56. BD Biosciences
57. Beam Therapeutics
58. Beijing 302 Hospital
59. Beijing Boren Hospital
60. Beijing Children's Hospital
61. Bellicum Pharmaceuticals
62. BioAgilytix
63. BioAnalytix
64. Biogen
65. BioMarin Pharmaceutical
66. BioTether Sciences
67. BioVec Pharma
68. bluebird bio
69. BridgeBio
70. Bristol-Myers Squibb
71. California Institute of Technology
72. Cambridge Gene Therapy
73. Carmine Therapeutics
74. Cartesian Therapeutics
75. Cartherics
76. Castle Creek Biosciences
77. Catalent
78. Catalyst Biosciences
79. CavoGene LifeSciences
80. CCRM
81. Celgene
82. Cell Therapy Catapult
83. Cellectis
84. CellGenTech
85. Cellular Biomedicine
86. Celonic
87. Celsion
88. CG Oncology
89. Changhai Hospital
90. Charles River Laboratories
91. Children's Hospital of Philadelphia
92. China Immunotech Biotechnology
93. Chinese PLA General Hospital
94. City of Hope
95. Clean Cells
96. CODA Biotherapeutics
97. Cognate BioServices
98. CombiGene
99. Copenhagen University Hospital
100. Copernicus Therapeutics
101. Creative Biolabs
102. CRISPR Therapeutics
103. CSL Behring
104. Cynvec
105. Cyprium Therapeutics
106. Cytovant Sciences
107. Daiichi Sankyo
108. DiNAQOR
109. DNAlite Therapeutics
110. DNAtrix
111. Duke University School of Medicine
112. Earle A. Chiles Research Institute
113. Editas Medicine
114. Emendo Biotherapeutics
115. Encoded Therapeutics
116. Endsulin
117. Enochian BioSciences
118. Entos Pharmaceuticals
119. Epeius Biotechnologies
120. Errant Gene Therapeutics
121. Esteve
122. Eurofins DiscoverX
123. Evotec
124. Excision BioTherapeutics
125. Exegenesis Bio
126. Expression Therapeutics
127. Eyevensys
128. FerGene
129. Ferring Pharmaceuticals
130. Flash Therapeutics
131. Flexion Therapeutics
132. Fortress Biotech
133. Fosun Pharma
134. Fred Hutchinson Cancer Research Center
135. Freeline Therapeutics
136. Fujian Cancer Hospital
137. Fujian Medical University
138. Gemini Therapeutics
139. Gene Therapy Research Institution
140. GeneCure Biotechnologies
141. Genelux
142. GeneMedicine
143. GeneQuine Biotherapeutics
144. Generation Bio
145. Genethon
146. Genocea
147. Genprex
148. GenSight Biologics
149. GenVec
150. GlaxoSmithKline
151. Glycostem Therapeutics
152. GOG Foundation
153. Gradalis
154. Gyros Protein Technologies
155. Gyroscope Therapeutics
156. Hadassah Medical Organization
157. Handl Therapeutics
158. Hebei Senlang Biotechnology
159. Helixmith
160. Hemera Biosciences
161. Henan Cancer Hospital
162. Henan Provincial People's Hospital
163. Herantis Pharma
164. Herlev Hospital
165. HiTech Health
166. Holostem Terapie Avanzate
167. Homology Medicines
168. HORAMA
169. Huapont Life Sciences
170. Human Stem Cells Institute PJSC (HSCI)
171. Ikarovec
172. Ilya Pharma
173. Immatics
174. Immunocore
175. ImmunXperts
176. Immusoft
177. Incyte
178. Inovio Pharmaceuticals
179. Intellia Therapeutics
180. Intertek
181. Invectys
182. Iovance Biotherapeutics
183. IVERIC bio
184. James and Esther King Biomedical Research Program
185. Janssen
186. JOINN Laboratories
187. Jonsson Comprehensive Cancer Center
188. Juno Therapeutics
189. Junshi Biosciences
190. JW Therapeutics
191. KAEDI
192. Karolinska Institute
193. Key Biologics
194. Kite Pharma
195. Kodikaz Therapeutic Solutions
196. Kolon TissueGene
197. Kriya Therapeutics
198. Krystal Biotech
199. KSQ Therapeutics
200. Kubota Vision
201. Kuur Therapeutics
202. Labcorp
203. Leiden University Medical Center
204. LentiStem Biotech
205. LEXEO Therapeutics
206. Limelight Bio
207. Lion TCR
208. Living Pharma
209. LogicBio Therapeutics
210. Lokon Pharma
211. Lonza
212. Lysogene
213. Lytix Biopharma
214. Masonic Cancer Center
215. MD Anderson Cancer Center
216. Medigene
217. MeiraGTx
218. Memorial Sloan-Kettering Cancer Center
219. Merck
220. Merck KGaA
221. Mesoblast
222. Mie University
223. Milo Biotechnology
224. Miltenyi Biomedicine
225. MingJu Therapeutics
226. Mitsubishi Tanabe Pharma
227. Momotaro-Gene
228. MultiVir
229. Mustang Bio
230. Myosana Therapeutics
231. Nanjing Medical University
232. Nantes University Hospital
233. National Cancer Institute
234. Navega Therapeutics
235. NeuExcell Therapeutics
236. Neuracle Genetics
237. Neurogene
238. Neurophth Therapeutics
239. Nexelis
240. Ninevah Therapeutics
241. Ningbo Cancer Hospital
242. Noga Therapeutics
243. Novartis
244. Ocugen
245. Oncolys BioPharma
246. Onconetics Pharmaceuticals
247. OncoSec
248. OncoSenX
249. ORCA Therapeutics
250. Orchard Therapeutics
251. Oxford Biomedica
252. OXGENE
253. Oxular
254. Pacific BioLabs
255. PACT Pharma
256. PAIRimmune
257. Passage Bio
258. Pattern Biosciences
259. PeriphaGen
260. Peter MacCallum Cancer Centre
261. Pfizer
262. Phio Pharmaceuticals
263. Phoenix Nest
264. PhorMed
265. PolyBioCept
266. Porton Bio
267. Poseida Therapeutics
268. PPD Laboratories
269. Precigen
270. Precision BioSciences
271. Precision for Medicine
272. Prevail Therapeutics
273. Prometheus Laboratories
274. Providence
275. PsiOxus Therapeutics
276. PTC Therapeutics
277. Public Health England (PHE)
278. Q2 Solutions
279. QualTex Laboratories
280. R&D systems
281. Reading Scientific Services
282. Redbiotec
283. Redpin Therapeutics
284. Regeneron Pharmaceuticals
285. REGENXBIO
286. Renova Therapeutics
287. resTORbio
288. Ring Therapeutics
289. Rocket Pharmaceuticals
290. Roswell Park Cancer Institute
291. Ruijin Hospital
292. San Raffaele Telethon Institute For Gene Therapy
293. Sangamo Therapeutics
294. Sarepta Therapeutics
295. SBH Sciences
296. Scancell
297. Selecta Biosciences
298. SGS
299. Shanghai Cell Therapy Research Institute
300. Shanghai Children's Medical Center
301. Shanghai Sunway Biotech
302. Shanghai Unicar-Therapy Bio-medicine Technology
303. Sheba Medical Center
304. Shenzhen BinDeBio
305. Shenzhen Geno-immune Medical Institute
306. Sibiono GeneTech
307. Sidney Kimmel Comprehensive Cancer Center
308. Siemens Healthineers
309. Sinobioway Cell Therapy
310. Solid Biosciences
311. Solvias
312. Soochow University
313. Sorrento Therapeutics
314. Spark Therapeutics
315. Spirovant Sciences
316. SpringWorks Therapeutics
317. St. Jude Children’s Research Hospital
318. STEMCELL Technologies
319. StrideBio
320. Sun Yat-sen University
321. Svar Life Science
322. SwanBio Therapeutics
323. Takara Bio
324. Targovax
325. TCR2 Therapeutics
326. TCRCure Biopharma
327. Tenaya Therapeutics
328. Tessa Therapeutics
329. Texcell
330. The First Affiliated Hospital of Zhejiang University
331. The Leukemia and Lymphoma Society
332. The Methodist Hospital System
333. The Netherlands Cancer Institute
334. The Ohio State University Comprehensive Cancer Center
335. Pregene Biotechnology
336. The Seventh Affiliated Hospital
337. TheraBiologics
338. THERAVECTYS
339. Third Military Medical University
340. Tmunity Therapeutics
341. Tolerion
342. TrakCel
343. Transgene
344. Trizell
345. Trucode Gene Repair
346. UAB (Universitat Autònoma de Barcelona)
347. Ultragenyx Pharmaceutical
348. UNC Lineberger Comprehensive Cancer Center
349. uniQure
350. University College London
351. University Health Network
352. University of Connecticut
353. University of Manchester
354. University of Minnesota
355. University of Munich
356. University of Pennsylvania
357. University of Pittsburgh
358. University of Southern California
359. Uppsala University
360. Urovant Sciences
361. UWELL Biopharma
362. VBL Therapeutics
363. VCN Biosciences
364. Verve Therapeutics
365. ViGeneron
366. Vivet Therapeutics
367. Voyager Therapeutics
368. Wellington Zhaotai Therapies
369. Wize Pharma
370. WuXi Advanced Therapies
371. WuXi AppTec
372. Wyvern Pharmaceuticals
373. Xiangxue Life Sciences
374. Xinqiao Hospital
375. Xuanwu Hospital
376. XyloCor Therapeutics
377. Yale University
378. Zelluna Immunotherapy
379. Zhujiang Hospital
380. Ziopharm Oncology

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.